This double-blinded, placebo-controlled, single ascending dose (SAD) study is designed to
evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity in
healthy subjects of a single dose of AV-380. AV-380 is an immunoglobulin (Ig) G1 monoclonal
antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15),
a cytokine involved in cancer-induced cachexia.